Assays in PCOS OUH

These have been described recently [10, 18] and are presented in the Additional file 1. During 1997–2003, an oral glucose tolerance test (OGTT) was part of the routine evaluation program for newly referred women with PCOS [20].

The Danish health registries

All Danish individuals are assigned a unique personal identification number and data from national registers can therefore be linked at an individual level. We retrieved information about hospital contacts and filled medicine prescriptions along with dates of death if applicable, for women with PCOS and control subjects from National Patient Register (NPR), the National Prescription Registry and the National Cause of Death Register from 1995 to December 31st 2015.

Outcome

The primary outcome was CVD defined as at least one of the following criteria: (1) the presence of a CVD diagnosis in NPR according to ICD10: E78 (dyslipidemia), G45–G46 (TCI), I10–13 (essential hypertension and hypertension with complications), I20 (angina), I21–25 (myocardial infarction and ichemic coronary disease), I26 (lung embolism), I50 (incompensatio cordis), I63–I64 (cerebral infarction), I65–I66 (occlusion of vertebral and cerebral arteries), I80–82 (venous thrombosis) or (2) prescription of drugs for treatment of CVD according to the National Prescriptions Registry database: antithrombotics (B01), antihypertensives (C02: alpha-blockers, C07: beta-blockers, C08: calcium-antagonists, C09: renin-angiotensin blockers), C10: antilipids. Patients should be medically treated for a certain time period and therefore, two or more medicine withdrawals should occur within the same ATC group to be included.

Exclusion criteria

Participants with CVD events occurring before and up till 3 months after the index date were excluded. Furthermore, women with the diagnoses E221 (hyperprolactinemia), E220 (acromegaly), E24 (Cushing’s syndrome), E25 (adrenogenital syndrome), and Q96 (Turner syndrome) were excluded from all study cohorts.

Exposure

A baseline diagnosis of obesity (E66), type 1 and type 2 diabetes and gestational diabetes (E10, E13, E11, E14, O24), infertility (N97, Z350), presence of comorbidity (defined as Charlson index ≥ 1), and use of OCP were used as exposures. Use of OCP [ATC codes G03AA and G03AB (combined progesterone and estrogen OCP), and G03HB01 (OCP containing cyproterone)] was defined as ≥ 2 dispenses of prescriptions in the National Prescription Registry (a minimum of 6 months treatment with OCP). The Charlson Comorbidity Index is based on 19 comorbid conditions [21] and was calculated from the ICD-10 operationalization by Quan et al. [22]. All covariates were defined before the index date.

Statistical analyses

Descriptive analyses for categorical variables were presented as frequencies and difference between PCOS and controls was evaluated by Chi square test. Continuous variables were tabulated as medians (with quartiles, Q1 and Q3) and nonparametric test on the equality of medians were used to test for differences between groups. P values below 0.05 were considered statistically significant.

Cox proportional hazard models were used to calculate incidence rates, hazard ratios (HR) and 95% confidence intervals (95% CIs) and corresponding P values for outcomes. The regression analyses including PCOS Denmark and controls with CVD as the outcome were carried out crude and adjusted for one of the exposures obesity, diabetes, infertility, comorbidity and use of OCP, and finally adjusted for all four variables: Obesity, diabetes, infertility and use of OCP. The diagnosis codes for diabetes and CVD are included as part of the Charlson index and therefore we did not adjust for Charlson score in the regression models. Regression analyses were repeated with CVD excluding hypertension and dyslipidemia as outcomes. The matching of PCOS and controls was taken into account by estimating stratified baseline hazard for each matching set.

The Cox proportional hazard analyses (regression analyses) in the PCOS OUH cohort were carried out crude and adjusted for age and BMI. Analyses were conducted using STATA 14 (StataCorp 2015). Data were anonymized according to Danish law and regulations, and therefore analyses were performed through a remote VPN access to Statistics Denmark.

Ethics

The core study was an open register-based cohort study. The study did not need approval from the local Ethics committee or Institutional Review Board by Danish law. The study was approved by the Data Protection Agency and by Statistics Denmark, Project No. 704175.

PCOS vs. controls (Additional file 1: Appendix Table S1)

The median age of women in PCOS Denmark was 29 years. By definition, the age was comparable in PCOS Denmark vs. controls. Women in PCOS Denmark had higher prevalence of ICD10 codes and medicine prescriptions related to the metabolic syndrome occurring before the index date compared to controls. The prevalence of comorbidity and infertility was higher in PCOS and the prescription of OCP and drugs for fertility treatment and the number of births before the index date (23% vs. 19% had ≥ 1 births) was higher in PCOS than controls.

Women in PCOS Denmark resembled women in PCOS OUH regarding age and ICD10 codes for the metabolic syndrome and comorbidity before the index date, but they had higher average number of births, lower prevalence of infertility diagnoses and lower prevalence of antidiabetic prescriptions.

Baseline clinical and biochemical data in PCOS OUH (Additional file 1: Appendix Table S2)

The median age of women in PCOS OUH was 29 years, BMI was 27.0 kg/m², 52% had waist ≥ 88 cm, 61% had BMI ≥ 25 kg/m², 38% had elevated systolic BP, 34% had elevated diastolic BP, and 18% had TG ≥ 1.7 mmol/L.

CVD event rates (Table 1)

Baseline characteristics according to subsequent development of CVD in PCOS OUH (Table 2)

Baseline characteristics according to development of CVD in PCOS Denmark and controls (Table 3): women with development of CVD including hypertension and dyslipidemia in PCOS Denmark vs. controls

PCOS Denmark and development of CVD yes vs. no

Women in PCOS Denmark who developed CVD were significantly older than women in PCOS Denmark without development of CVD (35 vs. 28 years, P < 0.001), the diagnoses obesity, diabetes, and presence of comorbidity were more common, whereas a diagnosis of infertility and use of OCP was lower. When hypertension and dyslipidemia was excluded from the diagnosis of CVD, the diagnosis obesity had similar prevalence at baseline irrespective of later CVD diagnosis (P = 0.15).

Proportional hazard regression analyses

BMI and metabolic risk in PCOS

We found that the cardiovascular risk in PCOS was closely associated with BMI. In PCOS Denmark, a baseline ICD10 diagnosis of obesity resulted in a HR between 2.4 and 2.7 for CVD. Further, we noted that 24% of women in PCOS OUH that developed CVD were lean by the time of PCOS diagnosis. These results were in accordance with previous studies who reported that the risk of CVD and/or stroke was attenuated but not normalized in women with PCOS after adjusting for BMI [5, 7, 24]. Our results regarding BMI and CVD were somewhat different from data regarding the risk of T2D in lean women with PCOS, where the risk of T2D was < 1% at time of PCOS diagnosis [20, 25] and the risk of T2D development during follow up was not increased compared to age-matched controls [4, 10]. Therefore, our data suggest that prospective screening for CVD is indicated also in lean women with PCOS, whereas prospective OGTT, fasting glucose or HbA1c measurements may not be necessary.

Blood pressure

Screening for metabolic syndrome includes measurement of BP, lipid status and assessment of glucose metabolism. In regression analyses, high baseline BP was an important predictor of CVD development. Furthermore, more than 30% women in PCOS OUH had BP ≥ 130/85 mmHg, and we previously reported a three times increased risk of the ICD10 code hypertension in PCOS Denmark vs. controls at baseline [18]. In a Chinese population of women with PCOS, women with hypertension had higher lipid, glucose, insulin, and HOMA-ir levels than women without hypertension also after adjusting for BMI [26], which suggested that elevated BP was a marker of metabolic risk. Our results support that BP should be measured in all women with PCOS irrespective of BMI.

Lipids

Elevated TG levels ≥ 1.7 mmol/L were found in 18% women in PCOS OUH, and in multiple regression analyses TG, LDL and total cholesterol levels were the best predictors of development of CVD and remained significant after adjusting for age and BMI. However, 66% of women in PCOS OUH that developed CVD had baseline TG < 1.7 mmol/L, which supported that other risk markers than lipid profile determined CVD risk in PCOS. Previous studies estimated that 70% women with PCOS had borderline or high lipid levels [27], but dyslipidemia depends on for example ethnicity [28] and age [29]. The inclusion of a relatively lean and young study population of predominantly Nordic origin could have affected our study results. Our data support the importance of performing a baseline lipid profile in PCOS as risk assessment, but treatment with statins is rarely indicated in women < 35 years [12].

Insulin resistance and glycemic status

HbA1c, fasting insulin, and HOMA-ir were higher at baseline evaluation in women in PCOS OUH with development of CVD compared to those not diagnosed with CVD. In multiple regression analyses, 2 h BG, fasting insulin, and HOMA-ir predicted development of CVD after adjusting for age and BMI, whereas HbA1c did not predict CVD risk. We could not confirm that HbA1c is a better predictor of CVD than fasting or 2 h glucose [30]. Median HbA1c was however relatively low in our study cohort, which could have affected study results. In PCOS Denmark, a baseline diagnosis of diabetes increased the risk of CVD more than threefold, confirming that women with PCOS and diabetes need special attention regarding risk of CVD.

Age

Age was a significant predictor for CVD in the present study, but the effect was moderate as the median age at CVD diagnosis was only 1 year lower in PCOS Denmark vs. controls and 90% vs. 88% was aged < 50 years at CVD diagnosis. BMI and age are closely associated [29, 31], but the significant association between age and CVD development remained significant after adjusting for BMI. Our data could reflect that hypertension may be diagnosed at a relatively young age, especially as BP is measured in all women during pregnancy, but the exclusion of hypertension as a CVD outcome still resulted in a relatively low medium age at CVD diagnosis. Mani et al. [32] found a prevalence of 27% for myocardial infarction and angina in women with PCOS aged > 65 years attending a specialized clinic in United Kingdom and the OR for myocardial infarction was 12.9 in women with PCOS aged > 65 years vs. controls [32]. The risk for stroke was not significantly increased in PCOS in the meta-analysis by Anderson et al., though the risk for stroke became significantly increased in PCOS when only studies in women of average age > 45 years were included [6]. Increasing age in PCOS was associated with higher blood pressure, more adverse lipid profile, and impaired beta cell function [29]. Therefore, the diagnosis pattern could differ significantly in peri- and postmenopausal study populations of women with PCOS. We could test this hypothesis by repeating the present study after longer follow up duration.

Androgen status

Testosterone levels at baseline did not predict development of CVD. Accordingly, we recently reported that the presence of individual Rotterdam criteria was not associated with cardio-metabolic diagnoses upon diagnosis in PCOS OUH despite a more adverse metabolic risk profile in women with polycystic ovaries and irregular menses [18]. Furthermore, testosterone levels did not predict the risk of T2D in PCOS OUH [10]. Importantly, mean BMI varies between different PCOS phenotypes [33, 34], and studies regarding vascular risk should adjust for BMI. Different results could be found in more obese study populations predominantly consisting of other PCOS phenotypes. Further prospective studies are needed to determine if the long-term cardiovascular risk is affected by PCOS phenotype independent of BMI.

OCP

OCP is often used to treat hyperandrogenism and irregular menses in PCOS. We found that treatment with OCP increased the risk of CVD in PCOS Denmark, but this became non-significant when dyslipidemia and hypertension was not considered a CVD outcome. The most straightforward explanation would be that OCP is generally not prescribed for women with hypertension, but the register based design of the present study limits the possibility of firm conclusions regarding this point. The present study design did not allow us to adjust for use of OCP after the diagnosis of PCOS. However, our data confirmed increased risk of VTE in PCOS [16] and that the risk of CVD increased further during use of OCP [7, 17]. Metabolic side-effects of OCP are a matter of discussion. We and others reported increased insulin levels during OGTT in women with PCOS treated with OCP [35, 36] along with weight gain [14], which could increase the risk of development of CVD. Furthermore, treatment with OCP was associated with increased activation of the coagulation system [15], which was associated with increased thromboembolic risk [17]. The present data support that the possible benefit of OCP on PCOS-related symptoms needs to be balanced against possible metabolic side effects in each patient.

Strengths and limitations

An important strength of this study was the nationwide data and the embedded cohort of PCOS OUH with available clinical and biochemical data, which allowed us to test hypotheses that could not be evaluated in the national cohort. Limitations to the study include the following. Women were diagnosed with PCOS through hospital contacts, hence some women in the control group may have undiagnosed PCOS, which could lead to underestimation of relative CVD risk in PCOS. However, undiagnosed PCOS likely represents milder cases. The Rotterdam criteria were introduced in 2003 [37], which implied the inclusion of more mild phenotypes as part of the PCOS definition. The use of different definitions of PCOS is a limitation of the present study. Furthermore, the study was conducted in a relatively lean and predominantly young Nordic study population with low baseline risk of CVD. Some ascertainment bias is possible, especially for potentially asymptomatic circulatory conditions such as hypertension and dyslipidemia, with PCOS patients potentially having more BP and lipid measurements done than population controls. The present study results need to be reproduced in study populations consisting of other phenotypes and with higher baseline metabolic risk. Our definition of CVD as an outcome was relatively broad and included both prevalent conditions such as hypertension and incident events such as myocardial infarction. We addressed this by defining a secondary study outcome without hypertension and dyslipidemia, and through tabulating the individual disease outcomes.

The present study design included baseline clinical and biochemical characteristics as predictors of CVD risk. PCOS is associated with higher serum levels of IL-6 and other inflammatory cytokines [2, 38], which could be associated with increased risk of CVD. Metabolic risk in PCOS could be related to IL-6 gene polymorphism [39] and the metabolic risk may be modified by lifestyle intervention [40] and metformin treatment [41]. More studies are needed regarding the long term effect of lifestyle and medical intervention on CVD risk in PCOS. Potential improvements to cohort studies like this could include collection of more sophisticated measures of baseline inflammatory markers and prospective measures of for example BMI and glycemic status.